A recent paper in the Journal of the American Medical Society has taken a look at insurance company data and found a link between people who take drugs that target this pathway and hospitalizations for pancreatitis. In general this is not good. The endocrine society has countered taking a dim view of the statistics in the paper.
There are two classes of drugs that target this pathway. The GLP-1 like peptides, and the DPP4 inhibitors. There already have been concerns with respect to cardiovascular effects of these drugs, so one more piece of bad news is a problem. For what its worth, my gut feeling is that it's a sampling error in the statistics. We are looking at a weak signal and humans being, the variable large omnivorous mammals that we are, require larger sample sizes to really compute meaningful result. If you look at the pre-selection criteria, these people were already quite ill with the host of complaints that plague those with diabetes. I would wait for more information before panic
There are two classes of drugs that target this pathway. The GLP-1 like peptides, and the DPP4 inhibitors. There already have been concerns with respect to cardiovascular effects of these drugs, so one more piece of bad news is a problem. For what its worth, my gut feeling is that it's a sampling error in the statistics. We are looking at a weak signal and humans being, the variable large omnivorous mammals that we are, require larger sample sizes to really compute meaningful result. If you look at the pre-selection criteria, these people were already quite ill with the host of complaints that plague those with diabetes. I would wait for more information before panic
RSS Feed
